CRISPR: A licence to heal

Few areas of emerging research have generated as much excitement in the life sciences community as CRISPR/Cas9, a gene-editing system which relies on the cas9 enzyme to alter DNA. But who invented it and who owns it?

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Genetics

Charpentier CRISPR patent gets good news from Japan

14 December 2023 Novelty and inventive step of patent owned by ERS Genomics and Emmanuelle Charpentier withstand challenge at Japan Patent Office | Invalidity proceedings also rejected by JPO in 2021.

Genetics

Will de-extinct animals be patent eligible in the US?

5 January 2023 Science fiction is becoming science fact but the Alice/Mayo framework throws up some interesting challenges to bringing life back from the dead, explains Brian Hausman of Baker Botts.

Genetics

Gene-editing bill: encouraging innovation or adding complexity?

26 May 2022 UK legislation to streamline gene-editing technology research is promising for innovation, but presents potential complications for IP, finds Sarah Speight.

More features

From Edwards to Insulet: Three key medical device cases of 2025

5 ways the USPTO director is changing US innovation

Mirum targets generics in quartet of suits over liver treatment

Hogan Lovells and Cadwalader strike historic deal to create $3.6bn firm

Regeneron v Alvotech: The big impact

SCOTUS shuts the door on Entresto ‘after-arising technology’ review

Morgan Lewis continues coast-to-coast US expansion with life sciences specialist

Beyond traditional IP: A comprehensive AI strategy for life sciences

CRISPR: A licence to heal

More on this story

Editor's picks

Editor's picks

More features